The two collaborators aim to develop a prophylactic vaccine based on Evaxion’s EDEN-discovered gonorrhea targets. “We are thrilled about this partnership. It offers a unique opportunity to deliver our EDEN-identified
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
Advertisement
NLS News
Karolinska University Hospital’s director Björn Zoëga and Karolinska Institute’s rector Annika Östman Wernerson have signed an agreement to establish a new joint center for advanced cell, gene and tissue therapies.
Evaxion Biotech has initiated a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen. The new vaccine project will be a collaboration between Evaxion and an
Orexo has announced the submission of the New Drug Application (NDA) to the US Food and Drug Administration for OX124, a high-dose rescue medication for opioid overdose with nasal delivery.
In June 2023, the Swedish Presidency of the Council of the European Union called for reinforcing, accelerating, and maximizing the benefits of fair and open research data in Europe, within
The aim of the research collaboration is to reveal the mechanism of action and pharmacological characterization of a drug candidate. Under the terms of the collaboration, Salipro Biotech will utilize
With the investment, Lauxera Capital Partners is joining with other investors, majority owner Bure Equity AB and Northislet AB, as well as with BioLamina’s founders and executives as shareholders in
FluoGuide has received an award from The Association of Listed Danish Growth Companies in the category of “Largest Stock Price Increase Since IPO”. “We are very pleased by the recognition
Elicera Therapeutics has received a Notice of Allowance from the Chinease Patent Office in its patent application relating to the use of the iTANK-technology in CAR T-cell therapies. Once granted, the
Mendus has received Fast Track Designation for its lead program, vididencel, for the treatment of Acute Myeloid Leukemia (AML) in complete remission with residual disease. “As part of the preparations
Beactica Therapeutics has selected BEA-17 as a preclinical candidate for its LSD1 programme, aimed at finding new therapies for aggressive brain tumors and other life-threatening cancers. “We are thrilled to
The former state epidemiologist has been awarded the prestigious BiotechBuilders Award 2023, for his contribution during the pandemic. The following justification was: “This year’s winner of the BiotechBuilders Award goes
Devyser and Thermo Fisher Scientific have agreed to expand commercial collaboration by including Brazil in the exclusive collaboration and distribution agreement for Devyser’s post-transplant portfolio of NGS products. In addition
Drug and Device Development
FluoGuide has announced results from a phase IIa trial of its lead product FG001 in lung cancer. FG001 was shown to illuminate the majority of the patients’ lung tumors and
Guard Therapeutics has announced top-line results from its AKITA study, evaluating RMC-035 for the prevention of kidney injury in open-heart surgery. Patient recruitment was prematurely stopped, and as expected the
Genmab and Seagen have announced that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received
The 15th patient with advanced hepatocellular carcinoma (HCC) has been included in the company’s ongoing phase 2a study. The study evaluates safety and efficacy with the candidate drug fostrox in
Herantis Pharma has announced that the dosing of the healthy volunteers in part 2 of the Phase 1a clinical study has been started based on decision from the Data and
Profile
The philosophical aspect of chemistry led Morten Meldal to the field and he loves, and cannot help thinking about, the next solution and the intriguing questions about our being and
Iris Öhrn considers herself a cosmopolitan person, and with good reason. The investment advisor for life science at Business Region Göteborg left her native Cuba to study and work abroad
Massachusetts Institute of Technology (MIT) in the US has produced more than its share of engineers and computer scientists, but unlike many of his peers, alumnus Dr. Robert Langer, ScD,
Careers
Isa Lindgren has been intrigued by all things science since she was a child. As Manager of Analytical Development at NorthX Biologics she gets to integrate her fascination with a
SwedenBIO has appointed the co-founder and operational manager of Sprint Bioscience, Jessica Martinsson, as its new Director General. “With her entrepreneurial experience and co-founder of a life science company, SwedenBIO
Evaxion Biotech has announced that its new Chief Executive Officer (CEO) Per Norlén has joined the company on October 3rd. “With Per at the steering wheel, we expect to bring
Careers
Surviving an episode of cancer as a teenager set Lao Saal on a path to seek out better ways to detect, monitor and treat the deadly cells. That determination drove him to earn medical and doctoral degrees at Columbia
JOB ALERTS
Read the latest issue of our magazine!
No 03 2023 // This issue includes an exclusive profile interview with Jonina Gudmundsdottir, the CEO of the Icelandic CDMO Coripharma, and a special report on leadership, including advice from leadership expert Pär Skoglund Finquist and Sarah Lidé, the founder of VILDA, a Swedish network for female CEOs in the life science industry.
Our hot topics in this issue are artificial intelligence in life sciences – renowned AI expert Professor Christian Guttmann shares his insight – and global trends within manufacturing of advanced biologics. In addition you may read about the vital role of venture capital in Norway, how the EU’s new pharmaceutical legislations may backfire for access to new medicines, and Niels Abel Bonde, MVA, emphasizes the importance of Nordic Research Infrastructures.
Last but not least, we have a special report on the opportunities of cross-border collaborations and we highlight the fast growing life science industry in the Baltics and the attractive US market. We also dig deeper into the history of collaboration in our Nordic region.
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
Life Sciences Baltics, the leading life sciences event in the Baltics, brings together top decision-makers, tech scouts, researchers, investors, and life sciences professionals worldwide, all in one place. Organized since
The LSX Nordic Congress is the leading senior executive strategy, investment and partnering conference for the Nordic region. It has been connecting life science and healthcare industry leaders with international
At this event, the pahrmaceutical, biotechnology and medical device communities come together and discuss strategies for operational success in clinical trials. OCT Nordics is the perfect platform for professionals from
BIO-Europe convenes over 5,000 attendees, representing 60 countries and 2,220+ companies, making the event the industry’s largest gathering of biopharma professionals in Europe. Digital Partnering will take place November 14–15,
The latest research news from the Nordic region
Science articles
An international team of scientists led by the University of Helsinki performed comprehensive mapping of structural alterations in cellular proteins during the aging process. In the study published in Molecular
The 2023 Ig Nobel Prizes celebrates for example backward reading and counting nostril hairs. The 2023 Ig Nobel Prizes were awarded at the 33rd First Annual Ig Nobel Prize ceremony,
Researchers at Karolinska Institutet have developed a molecular method able to detect whether or not bacteria respond to antibiotics within minutes. The findings are presented in the journal Nature Microbiology
Professor Jens Juul Holst has made discoveries that have strongly influenced how people with obesity or type 2 diabetes are treated today. Throughout a long career, this internationally recognized researcher
Professor Åslaug Helland is the recipient of the King Olav Vs Cancer Research Award 2023. “This is a great honor, and I am very happy about this recognition of the
In January 2023, the European Association for the Study of Obesity (EASO) and the Novo Nordisk Foundation (NNF) announced that they were establishing a new prize for an agenda-setting researcher
Nordic Life Science
The latest clinical trials
Guard Therapeutics has announced top-line results from its AKITA study, evaluating RMC-035 for the prevention of kidney injury in open-heart surgery. Patient recruitment was prematurely stopped, and as expected the
Genmab and Seagen have announced that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received
The 15th patient with advanced hepatocellular carcinoma (HCC) has been included in the company’s ongoing phase 2a study. The study evaluates safety and efficacy with the candidate drug fostrox in
Herantis Pharma has announced that the dosing of the healthy volunteers in part 2 of the Phase 1a clinical study has been started based on decision from the Data and
Calliditas Therapeutics has announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon in adults with Primary IgA nephropathy (IgAN). The Phase 3
Annexin Pharmaceuticals has announced that an independent evaluation of potential signals of effect has been carried out in the company’s Phase 2-study in retinal vein occlusion with the investigational new
Ultimovacs has announced the completion of enrollment of 75 patients and that the last patient has received the first dose in the FOCUS study. “We are pleased to announce the
Bavarian Nordic has announced topline results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial of its virus-like particle (VLP)-based chikungunya virus vaccine candidate, CHIKV VLP, in adults and adolescents
Alligator Bioscience has announced positive second interim results from the ongoing OPTIMIZE-1 Phase 2 study of the company’s lead asset mitazalimab in 1st line metastatic pancreatic cancer. The open-label, multi-center
Sign up to our newsletter